You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

RSV in Older Adults: The Promise of New Vaccine Technology

  • Authors: Susan J. Mayor, PhD; Stefania Maggi, MD, PhD, MPH
  • CPD Released: 5/30/2023
  • Valid for credit through: 5/30/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.25 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, infectious disease specialists, and pediatricians.

The goal of this activity is for learners to be better able to understand the current status of RSV vaccine developments.

Upon completion of this activity, participants will:

  • Demonstrate greater confidence in their
    • Understanding of the burden of RSV disease in older adults
    • Understanding of how new vaccine technologies are applied to RSV vaccine development


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Host

  • Susan J. Mayor, PhD

    Medical Journalist
    London, United Kingdom    

    Disclosures

    Susan J. Mayor, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Biotech, Inc.; Moderna, Inc.; Novartis; Novo Nordisk; Nutricia; Pfizer, Inc.; Prothya Biosolutions; Rhythm Pharmaceuticals; Sanofi; Wave Healthcare Communications Ltd
    Speaker or member of speakers bureau for: Edwards Lifesciences (former)

Faculty

  • Stefania Maggi, MD, PhD, MPH

    Geriatrician and Epidemiologist
    CNR Aging Branch, Institute of Neuroscience
    Padua, Italy

    Disclosures

    Stefania Maggi, MD, PhD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: Merck; Pfizer, Inc.
    Speaker or member of speakers bureau for: GlaxoSmithKline; Janssen Biotech, Inc.; Merck; Pfizer, Inc.; Sanofi; Viatris
    Research funding from: Sanofi

Editor

  • Alessia Piazza, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Alessia Piazza, PhD, has no relevant financial relationships. 

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

RSV in Older Adults: The Promise of New Vaccine Technology

Authors: Susan J. Mayor, PhD; Stefania Maggi, MD, PhD, MPHFaculty and Disclosures

CPD Released: 5/30/2023

Valid for credit through: 5/30/2024, 11:59 PM EST

processing....

Transkription in Deutsch

Download the pdf.

 

« Return to: RSV in Older Adults: The Promise of New Vaccine Technology
  • Print